Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-6236 plus pembrolizumab with or without chemotherapy in advanced RAS-mutated non-small cell lung cancer
NL-OMON60836Phase 1Recruiting
- Sponsor
- Revolution Medicines
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of daraxonrasib and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Revolution Medicines. Started Aug 2024; status: recruiting.
02
Drugs
daraxonrasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60836.